Ceregene
Independent informational resource focused on gene therapy and neurotrophic factor research for neurological and ocular diseases. The site documents development and translational strategies for AAV-mediated gene delivery of neurotrophic factors aimed at neuroprotection and functional restoration across indications such as Alzheimer’s disease, Parkinson’s disease, ALS, and retinal degenerations. Content is curated and reviewed by an editorial team and distinguishes between preclinical, early clinical, and established evidence.
Industries
N/A
Nr. of Employees
medium (51-250)
Products
AAV-mediated NGF gene therapy for Alzheimer’s disease
Intracerebral delivery of an NGF-encoding AAV vector targeting cholinergic-rich brain regions to support cholinergic neuron survival and function; progressed through Phase I clinical evaluation with planning for Phase II.
AAV-mediated neurturin gene therapy for Parkinson’s disease
Localized delivery of a neurturin-encoding AAV vector to dopamine-rich brain regions to support survival and function of dopaminergic neurons; advanced into multi-center Phase II clinical trials.
AAV-mediated IGF-1 gene therapy for ALS (preclinical)
Development-stage gene therapy delivering IGF-1 to motor neurons to enhance motor neuron survival and function; currently in preclinical optimization.
AAV-mediated neurotrophic factor therapies for retinal degenerations (preclinical)
Intraretinal delivery of neurotrophic factor genes (e.g., NT4/5 and related factors) to preserve photoreceptors and retinal function across diverse genetic causes of retinal degeneration.
AAV-mediated NGF gene therapy for Alzheimer’s disease
Intracerebral delivery of an NGF-encoding AAV vector targeting cholinergic-rich brain regions to support cholinergic neuron survival and function; progressed through Phase I clinical evaluation with planning for Phase II.
AAV-mediated neurturin gene therapy for Parkinson’s disease
Localized delivery of a neurturin-encoding AAV vector to dopamine-rich brain regions to support survival and function of dopaminergic neurons; advanced into multi-center Phase II clinical trials.
AAV-mediated IGF-1 gene therapy for ALS (preclinical)
Development-stage gene therapy delivering IGF-1 to motor neurons to enhance motor neuron survival and function; currently in preclinical optimization.
AAV-mediated neurotrophic factor therapies for retinal degenerations (preclinical)
Intraretinal delivery of neurotrophic factor genes (e.g., NT4/5 and related factors) to preserve photoreceptors and retinal function across diverse genetic causes of retinal degeneration.
Services
Curation, synthesis, and publishing of evidence-based summaries and analyses of peer-reviewed literature and clinical data related to gene therapy and neurotrophic factors.
Curation, synthesis, and publishing of evidence-based summaries and analyses of peer-reviewed literature and clinical data related to gene therapy and neurotrophic factors.
Expertise Areas
- Gene therapy development for neurological diseases
- AAV vector design and modification
- Neurotrophic factor therapeutic research
- Preclinical safety and efficacy studies
Key Technologies
- Adeno-associated virus (AAV) vector-mediated gene delivery
- Stereotactic intracerebral delivery
- Intraretinal gene delivery
- Neurotrophic factor gene therapy
News & Updates
Article summarizing research on rapid trust judgments by the human brain with reference to primary literature.
Discussion of the brain's reward circuitry and dopamine in the context of gaming apps.
Exploration of potential cognitive benefits and emotional risks associated with online gambling behaviors.
Completed Phase I clinical evaluations for targeted intracerebral delivery of neurotrophic factor gene therapies in Alzheimer’s and Parkinson’s disease.
Article summarizing research on rapid trust judgments by the human brain with reference to primary literature.
Discussion of the brain's reward circuitry and dopamine in the context of gaming apps.
Exploration of potential cognitive benefits and emotional risks associated with online gambling behaviors.
Completed Phase I clinical evaluations for targeted intracerebral delivery of neurotrophic factor gene therapies in Alzheimer’s and Parkinson’s disease.